VivoSeq
Other

Tyrosine Kinase Inhibitors

0

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Tyrosine Kinase Inhibitors is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Bristol-Myers Squibb, Sichuan Huiyu Pharmaceutical Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalS

Sichuan Huiyu Pharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Active, not recruiting3 · 20%
Unknown status3 · 20%
Recruiting2 · 13%
Terminated1 · 7%

Clinical Trials

Trial Activity

15 trials

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
Recruiting·Xxuna·N/A·NCT05341050·260 enrolled
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT06712680·115 enrolled
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
Active, not recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT05219318·22 enrolled
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03610971·24 enrolled
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Active, not recruiting·UUniversity of Colorado, Denver·Phase 1/2·NCT05845671·12 enrolled
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT01188278·173 enrolled
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Completed·UUNC Lineberger Comprehensive Cancer Center·N/A·NCT03885830·45 enrolled
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Completed·MMedical College of Wisconsin·Phase 2·NCT02269267·173 enrolled
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
Completed·UUniversity of Colorado, Denver·Phase 1·NCT04541407·1 enrolled
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Completed·Novartis logoNovartis·Phase 2·NCT04795427·84 enrolled
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Completed·NNational OncoVenture·Phase 2·NCT01718847·40 enrolled
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Terminated·Novartis logoNovartis·Phase 3·NCT02108951·20 enrolled
A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
Unknown status·LLady Davis Institute·Phase 1·NCT02321293·20 enrolled
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
Unknown status·TThe University of Hong Kong·Phase 2·NCT03647956·40 enrolled
Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes
Unknown status·—·N/A·NCT04326933·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)